{
  "report_rows": [
    {
      "kpi": "Revenue per Treatment ($)",
      "prediction": "MISS",
      "answer": "pred ~$411 vs. cons $414.21",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Treatment Volume Growth (YoY %)",
      "prediction": "BEAT",
      "answer": "pred ~+0.55% vs. cons +0.40%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. Operating Income",
      "prediction": "MISS",
      "answer": "pred ~$575M vs. cons $580.5M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY Adj. OI (FY 2026)",
      "prediction": "LOWER",
      "answer": "guide mid ~$2,200M vs. cons $2,244M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY Adj. EPS (FY 2026)",
      "prediction": "LOWER",
      "answer": "guide mid ~$14.65 vs. cons $14.88",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY Volume Growth (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide +25-50bps vs. cons +0.40%",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY RPT Growth (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 1-2%, cautious tone vs. cons ~+0.8% implied",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -8.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -10.0,
  "day5_path": "FADE",
  "day5_rationale": "FADE \u2014 sell-side estimate cuts on implied H2 OI reduction (~$39M below consensus H2) drive continued drift; no squeeze cushion (short interest at multi-year lows); multiple re-rating pauses after two consecutive Archetype A prints",
  "day5_confidence": "MEDIUM"
}